Major reduction in plasma Lp(a) levels during sepsis and barns

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 4, 2000, Pages 1137-1142

  Mooser, Vincent ^a   Berger, Mette M ^a   Tappy, Luc ^a   Cayeux, Christine ^a   Marcovina, Santica M ^b   Darioli, Roger ^a   Nicod, Pascal ^a   Chioléro, René ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Northwest Lipid Research Laboratories   (United States)

Author keywords

Apolipoprotein(a); Burns; Inflammation; Lipoprotein(a); Sepsis

Indexed keywords

ACUTE PHASE PROTEIN; APOLIPOPROTEIN A; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; BURN; CELL SURVIVAL; CLINICAL ARTICLE; CYTOKINE RELEASE; FEMALE; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SEPSIS; WOUND HEALING;

EID: 0034083644     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.4.1137     Document Type: Article

References (44)

1. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246: 904-910.
2. Scanu AM. Lipoprotein(a): a genetic risk factor for premature coronary heart disease. JAMA. 1992;267:3326-3329.
3. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Semal LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA. 1996;276:544-548.
4. Albers JJ, Marcovina SM, Lodge MS. The unique lipoprotein(a): properties and immunochemical measurement. Clin Chem. 1990;36: 2019-2026.
5. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
6. Mooser V, Sheer D, Marcovina SM, Wang J, Guerra R, Cohen J, Hobbs HH. The apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African-Americans. Am J Hum Genet. 1997;61:402-417.
7. Espeland MA, Marcovina SM, Miller V, Wood PD, Wasilauskas C, Sherwin R, Schrott H, Bush TL. Effect of post-menopausal hormone therapy on lipoprotein(a) concentration: PEPI Investigators: postmenopausal estrogen/progestin interventions. Circulation. 1998;97:979-986.
8. Thillet J, Doucet C, Issad B, Allouache M, Chapman JM, Jacobs C. Elevated Lp(a) levels in patients with end-stage renal disease. Am J Kidney Dis. 1994;23:620-621.
9. Kronenberg F, Konig P, Neyer U, Avinger M, Prisbanig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110-120.
10. Mooser V, Marcovina SM, Wang J, Hobbs HH. High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: implications for plasma Lp(a) assay. Clin Genet. 1997;52: 387-392.
11. van der Hoek YY, Wanders RJA, van den Ende AE, Kraft HG, Gabel BR, Kastelein JJP, Koschinsky ML. Lipoprotein(a) is not present in the plasma of patients with some peroxisomal disorders. J Lipid Res. 1997; 38:1612-1619.
12. Fontana P, Mooser V, Bovet P, Shamlaye C, Burnand B, Lenain V, Marcovina SM, Riesen W, Darioli R. Dose-dependent inverse relationship between alcohol consumption and serum Lp(a) levels in Black African Males. Arterioscler Thromb Vasc Biol. 1999;19:1075-1082.
13. Périard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Marcovina SM, Glauser MP, Nicod P, Darioli R, Swiss HIV Cohort Study, Mooser V. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999;100:700-705.
14. Berglund L. Diet and drug therapy for lipoprotein(a). Curr Opin Lipidol. 1995;6:48-56.
15. Ledue TB, Neveux LM, Palomaki GE, Ritchie RF, Craig WY. The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. Clin Chem Acta. 1993;223:73-82.
16. Slunga L, Johnson O, Dahlen GH, Eriksson S. Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Invest. 1992;52:95-101.
17. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989;78:145-150.
18. Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature. 1987;330:113-114.
19. Alvarez C, Ramos A. Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem. 1986;32:142-145.
20. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, Barie PS, Rubin AL. Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med. 1996;24: 584-589.
21. Fraunberger P, Pilz G, Cremer P, Werdan K, Walli AK. Association of serum tumor necrosis factor levels with decrease of cholesterol during septic shock. Shock. 1998;10:359-363.
22. Akgun S, Ertel NH, Mosenthal A, Oser W. Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. J Lab Clin Med. 1998;131:103-108.
23. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;100:1644-1655.
24. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Suter PM, Thijs LG. The SOFA (Sepsis-Related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707-710.
25. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41:246-255.
26. Mooser V, Tinguely F, Fontana P, Lenain V, Vaglio M, Ruchat P, von Segesser LK, Marcovina SM, Markert M, Darioli R, Nicod P. Effect of cardiopulmonary bypass and heparin on plasma levels of Lp(a) and apo(a) fragments. Arterioscler Thromb Vasc Biol. 1999;19:1060-1065.
27. Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina SM, Hobbs HH. Apo(a) kringle-4 containing fragments in human urine: relationship to plasma levels of lipoprotein(a). J Clin Invest. 1996;97: 858-864.
28. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest. 1996;98:2414-2424.
29. Liaudet L, Rosselet A, Schaller MD, Markert M, Perret C, Feihl F. Nonselective versus selective inhibition of inducible nitric oxide synthase in experimental endotoxic shock. J Infect Dis. 1998;177:127-132.
30. Mancini FP, Newland DL, Mooser V, Murata J, Marcovina SM, Young SG, Hammer RE, Sanan DS, Hobbs HH. Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta in mice. Arterioscler Thromb Vasc Biol. 1995;15: 1911-1916.
31. Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger G, Steyrer E, Kostner GM. Urinary excretion of apo(a) fragments: role in apo(a) catabolism. Arterioscler Thromb Vasc Biol. 1996;16:905-911.
32. Deutschmann CS, Andrejko KM, Haber BA, Bellin L, Elenko E, Harrison R, Taub R. Sepsis-induced depression of rat glucose-6-phosphatase gene expression and activity. Am J Physiol. 1997;273:R1709-R1718.
33. Filep JG, Delalandre A, Beauchamp M. Dual role for nitric oxide in the regulation of plasma volume and albumin escape during endotoxin shock in conscious rats. Circ Res. 1997;81:840-847.
34. Pannen HJ, Robotham JL. The acute-phase response. New Horiz. 1995; 3:183-197.
35. Frazer KA, Narla G, Zhang JL, Rubin EM. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat Genet. 1995;9:424-431.
36. Haffner S, Orchard T, Stein E, Schmidt D, LaBelle P. Effect of simvastatin on Lp(a) concentrations. Clin Cardiol. 1995;18:261-267.
37. Gregg RE, Wetterau JR. The molecular basis of abetalipoproteinemia. Curr Opin Lipidol. 1994;5:81-86.
38. Menzel HJ, Dieplinger H, Lackner C, Hoppichler F, Lloyd JK, Muller DR, Labeur C, Talmud PJ, Utermann G. Abetalipoproteinemia with an apoB-100-lipoprotein(a) glycoprotein complex in plasma: indication for an assembly defect. J Biol Chem. 1990;265:981-986.
39. Gabel BR, Koschinsky ML. Sequences within apolipoprotein(a) kringle IV types 6-8 bind directly to low-density lipoprotein and mediate non-covalent association of apolipoprotein(a) with apolipoprotein B-100. Biochemistry. 1998;37:7892-7898.
40. White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem. 1994;269: 28716-28723.
41. Ramharack R, Barkalow D, Spahr MA. Dominant negative effect of TGF-b1 and TNF-a on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol. 1998;18:984-990.
42. Navasa M, Gordon DA, Hariharan N, Jamil H, Shigenaga JK, Moser A, Fiers W, Pollock A, Grunfeld C, Feingold KR. Regulation of microsomal triglyceride transfer protein mRNA expression by endotoxin and cytokines. J Lipid Res. 1998;39:1220-1230.
43. Yokoyama K, Ishibashi T, Yi-qiang L, Nagayoshi A, Teramoto T, Maruyama Y. Interleukin-1 beta and interleukin-6 increase levels of apolipoprotein B mRNA and decrease accumulation of its protein in culture medium of HepG2 cells. J Lipid Res. 1998;39:103-113.
44. Kutteh WH, Rainey WE, Carr BR. Regulatory effects of multifunctional cytokines and steroid hormones on apolipoprotein B production by human fetal hepatocytes. J Soc Gynecol Invest. 1994;1:256-263.